FY2025 · period end Jun '25 · from the 10-K filed Aug 22, 2025
| Metric | FY25Jun '25 | FY24Jun '24 | FY23Jun '23 | FY22Jun '22 | FY21Jun '21 |
|---|---|---|---|---|---|
| Revenue | $1.22B |
Showing the most recent 5 annual periods. Get 15 years of history on the Pro plan, or unlimited history back to 1993 plus the smart-money dataset and webhooks on Institutional.
Figures a later SEC filing revised by more than 0.5% from what was originally reported. Each diff compares the same XBRL tag across two filings, so you can open both and check it yourself.
Operating Income (Loss)
FY 2013
Revised down 99.9% — reported in a 10-K.
As first reported
$158.5MAs it stands now
$158.5KNet Income (Loss) Attributable to Parent
Q2 2016
Revised up 18.3% — reported in a 10-K.
As first reported
$6.3MAs it stands now
$7.5MAny P/E built on the original filing overstated the true multiple by 15.5% — and stayed wrong from Feb 9, 2017 to Aug 27, 2018.
Net Income (Loss) Attributable to Parent
Q1 2016
Revised up 15.7% — reported in a 10-K.
As first reported
$16.3MAs it stands now
$18.8MAny P/E built on the original filing overstated the true multiple by 13.6% — and stayed wrong from Nov 9, 2016 to Aug 27, 2018.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest
Q1 2016
Revised up 15.2% — reported in a 10-Q.
As first reported
$24.1MAs it stands now
$27.8MOperating Income (Loss)
Q1 2016
Revised up 14.6% — reported in a 10-Q.
As first reported
$25.4MAs it stands now
$29.2MIncome (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest
Q2 2016
Revised up 12.2% — reported in a 10-Q.
As first reported
$13.5MAs it stands now
$15.2MRestatements are detected by comparing every vintage of a fact across all of BIO-TECHNE Corp's filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows TECH's most significant revisions, and a figure absent from it has not been certified as unrevised.
| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 8-K | 0001999371-26-013527 | Jun 23, 2026 | Jun 26, 2026 | Jun 25, 2026 22:49 UTC | EDGAR |
| 8-K | 0001999371-26-013429 | Jun 25, 2026 | Jun 25, 2026 | Jun 25, 2026 12:21 UTC | EDGAR |
| 8-K | 0001104659-26-055887 | May 6, 2026 | May 6, 2026 | May 6, 2026 10:30 UTC | EDGAR |
| 10-Q | 0001104659-26-056302 | Mar 31, 2026 | May 6, 2026 | May 6, 2026 20:31 UTC | EDGAR |
| 8-K | 0001104659-26-013412 | Feb 9, 2026 | Feb 11, 2026 | Feb 11, 2026 21:30 UTC | EDGAR |
| 8-K | 0001104659-26-009994 | Feb 4, 2026 | Feb 4, 2026 | Feb 4, 2026 11:30 UTC | EDGAR |
| 10-Q | 0001104659-26-010335 | Dec 31, 2025 | Feb 4, 2026 | Feb 4, 2026 21:31 UTC | EDGAR |
| 8-K | 0001104659-25-106631 | Oct 30, 2025 | Nov 5, 2025 | Nov 5, 2025 11:31 UTC | EDGAR |
Direct links to SEC EDGAR. TECH has additional filings available on the SEC site.
Who is buying and selling BIO-TECHNE Corp — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on TECH yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows, every figure pinned to its SEC filing. Be the first: run equity_research_brief on TECH and publish the result to your public profile.
Get 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate with zero survivorship bias.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs| $1.14B |
| $1.11B |
| $0.93B |
| Gross Profit | $0.79B | $0.77B | $0.77B | $0.76B | $0.63B |
|---|
| Operating Income | $0.10B | $0.21B | $0.30B | $0.30B | $0.24B |
|---|
| Net Income | $0.07B | $0.17B | $0.29B | $0.27B | $0.14B |
|---|
| EPS (Diluted) | $0.46 | $1.05 | $1.76 | $1.66 | $0.87 |
|---|
| Metric | FY25Jun '25 | FY24Jun '24 | FY23Jun '23 | FY22Jun '22 | FY21Jun '21 |
|---|---|---|---|---|---|
| Total Assets | $2.56B | $2.70B | $2.64B | $2.29B | $2.26B |
| Total Liabilities | — | — | — | — | — |
| Stockholders' Equity | $1.92B | $2.07B | $1.97B | $1.70B | $1.57B |
| Cash & Equivalents | $0.16B | $0.15B | $0.18B | $0.17B | $0.20B |
| Total Debt | $0.35B | $0.32B | $0.35B | $0.24B | $0.33B |
| Metric | FY25Jun '25 | FY24Jun '24 | FY23Jun '23 | FY22Jun '22 | FY21Jun '21 |
|---|---|---|---|---|---|
| Operating Cash Flow | $0.29B | $0.30B | $0.25B | $0.33B | $0.35B |
| Capital Expenditures | $0.03B | $0.06B | $0.04B | $0.04B | $0.04B |
| Free Cash Flow | $0.26B | $0.24B | $0.22B | $0.28B | $0.31B |
| Metric | FY25Jun '25 | FY24Jun '24 | FY23Jun '23 | FY22Jun '22 | FY21Jun '21 |
|---|---|---|---|---|---|
| Gross Margin | 64.8% | 66.4% | 67.7% | 68.4% | 68.0% |
| Operating Margin | 0.1% | 0.2% | 0.3% | 0.3% | 0.3% |
| Net Margin | 0.1% | 0.1% | 0.3% | 0.2% | 0.2% |
| Return on Equity | 3.7% | 8.3% | 15.6% | 16.6% | 9.5% |
| Return on Assets | 2.8% | 6.3% | 11.6% | 11.9% | 6.5% |
| Debt / Equity | 0.18× | 0.15× | 0.18× | 0.14× | 0.21× |
